Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-dose, randomized, open-label, three-way crossover comparative bioavailability study of RIZAPORT® 10 mg, Maxalt®-MLT 10 mg orally disintegrating tablets and Maxalt®-Lingua 10 mg oro-dispersible tablets

Trial Profile

A single-dose, randomized, open-label, three-way crossover comparative bioavailability study of RIZAPORT® 10 mg, Maxalt®-MLT 10 mg orally disintegrating tablets and Maxalt®-Lingua 10 mg oro-dispersible tablets

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2018

At a glance

  • Drugs Rizatriptan (Primary) ; Rizatriptan
  • Indications Migraine
  • Focus Pharmacokinetics; Registrational
  • Sponsors IntelGenx Corp.
  • Most Recent Events

    • 20 Nov 2018 According to an IntelGenx Corp media release, US FDA has accepted for review the resubmission of the 505(b)(2) New Drug Application (NDA) RIZAPORT oral soluble film 10 mg for the treatment of acute migraines. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date for completion of the review of the RIZAPORT NDA of April 1, 2019.
    • 31 Oct 2018 According to an IntelGenx Corp media release, the Spanish Agency of Medicines and Medical Devices (AEMPS) has granted national marketing authorization for RIZAPORT (10mg) in Spain.
    • 01 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top